Sector News

Endo CEO touts ‘exciting’ $2.2B bid for Auxilium

September 17, 2014
Life sciences
Endo’s got a deal for Auxilium Pharmaceuticals in mind. CEO Rajiv De Silva thinks it could be a home run, and analysts seem to agree. Auxilium, however, needs some time to think it over, and it’s swallowed a poison pill to make sure it gets just that.
 
Chesterbrook, PA-based Auxilium took up the defense plan Wednesday after receiving Endo’s $2.2 billion cash-and-stock offer, which amounts to a 31% premium on its Tuesday closing price. The poison pill will provide its board with “sufficient time to make informed judgments,” the company said
 
Endo, on the other hand, is “ready to engage immediately with Auxilium, complete our confirmatory diligence, negotiate a definitive agreement and complete this exciting transaction,” De Silva said in a statement. And the way Sterne Agee analyst Shibani Malhotra sees it, it’s no wonder: A deal could provide $0.39 (9%) EPS accretion in 2015 and $0.83 (17%) accretion in 2016. And it comes with the potential for tax synergies to increase those figures down the line, he wrote in a note to clients.
 
Thing is, Auxilium already has a deal of its own in the works for Canadian eye-drug maker QLT–and De Silva has suggested it’ll be one or the other. “Our offer is for Auxilium only,” he said on a Tuesday conference call, as quoted by Reuters. “We would leave it up to Auxilium’s management and its board to come to its own conclusions on how they view our transaction versus the transaction with QLT.”
 
But with portfolios Endo called “highly complementary,” the Malvern, PA-based pharma likes its chances. Auxilium’s 12 FDA-approved products–including Xiaflex, which treats curvature of the penis–would fit right in with its own men’s health and pain offerings, it figures. And it could pile product and location synergies onto the $75 million in cost savings it anticipates squeezing out of a merged company’s operating expenses.
 
As such, Canaccord Genuity analyst Corey Davis, for one, thinks Endo will ultimately prevail in making Auxilium its latest conquest in a string of recent deals. “We think the deal has an uber-high probability of being consummated,” he wrote in a note to clients. “Although Endo was light on number-detail, it would obviously be accretive and is a great first step in the right direction of buying things to maximize [Endo’s] terminal multiple.”
 
By Carly Helfand
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”